ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2004
Prognostic value of cell-cycle markers in ocular adnexal lymphoma: an assessment of 230 cases.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 119 citations in OpenAlex.
- Bilateral eyelid masses and enophthalmos as the initial manifestation of diffuse large B-cell lymphoma: a case report.Journal of medical case reports · 2025Article
- Marginal zone lymphoma of mucosa associated lymphoid tissue-lymphoma of the lacrimal gland in a young patient with Klinefelter syndrome: a case report.Journal of medical case reports · 2024Article
- Ocular adnexal mucosa-associated lymphoid tissue lymphoma: a narrative review.Journal of Yeungnam medical science · 2022Article
- Primary non-Hodgkin diffuse large B-cell lymphoma of the lacrimal sac: a rare case of aggressive tumor and literature review.Medicine and pharmacy reports · 2021Article
- Single-fraction low-energy electronic brachytherapy for conjunctival lymphoma.Journal of contemporary brachytherapy · 2020Article
- Mucosa-associated lymphoid tissue lymphoma on right lower eyelid previously diagnosed as lymphoid hyperplasia.Archives of craniofacial surgery · 2019Article
- Classification, diagnosis, and management of conjunctival lymphoma.Eye and vision (London, England) · 2019Review
- Ocular adnexal marginal zone lymphoma of mucosa-associated lymphoid tissue.Clinical and experimental medicine · 2018Review
- Primary Orbital Follicular Lymphoma: A Case Report and Review.Journal of clinical and diagnostic research : JCDR · 2017Article
- Clinicopathological Analysis of Ocular Adnexal Extranodal Marginal Zone B-Cell Lymphoma with IgG4-Positive Cells.PloS one · 2015Article
- Rituximab as Single Agent in Primary MALT Lymphoma of the Ocular Adnexa.BioMed research international · 2015Article
- A reappraisal of the diagnostic and therapeutic management of uncommon histologies of primary ocular adnexal lymphoma.The oncologist · 2013Review
- Conjunctival mass as an initial presentation of mantle cell lymphoma: a case report.BMC research notes · 2012Article
- Systemic non-Hodgkin's lymphoma involving the orbit and leptomeninges.Digital journal of ophthalmology : DJO · 2010Article
- Review
- Expression of p16 in conjunctival intraepithelial neoplasia does not correlate with HPV-infection.The open ophthalmology journal · 2008Article
- Interferon alpha eye drops: treatment of atypical lymphoid hyperplasia with secondary alopecia.The British journal of ophthalmology · 2007Article
- Primary lymphoma of the lacrimal sac: an EORTC ophthalmic oncology task force study.The British journal of ophthalmology · 2006Article
- [Diseases of the lacrimal gland].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2005Article
- Plasmacellular differentiation in extranodal marginal zone B cell lymphomas of the ocular adnexa: an analysis of the neoplastic plasma cell phenotype and its prognostic significance in 136 cases.The British journal of ophthalmology · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo determine the prognostic value of cell-cycle associated markers in ocular adnexal lymphoma (OAL).
methodsTwo hundred sixty-one consecutive cases of ocular adnexal lymphoproliferative lesions were subdivided into reactive lymphoid hyperplasia (RLH), atypical lymphoid hyperplasia (ALH) and OAL. The latter were sub-typed according to the new WHO Lymphoma Classification. All lesions were investigated applying standard immunohistochemical methods with antibodies specific for pRB, p53, p16, p21, BCL-6 and for multiple myeloma oncogene-1-protein (MUM1, also known as IRF4). The main endpoints included the development of a local recurrence, of systemic disease and of lymphoma-related death. The association of prognostic variables with endpoints was assessed by multiple logistic and Cox regression models, respectively.
resultsThe ocular adnexal lymphoproliferative lesions were categorised as OAL ( n=230; 88%), RLH ( n=29; 11%), and ALH ( n=2; 1%). The major lymphoma subtypes included 136 extranodal marginal zone B-cell lymphoma (EMZL), 31 diffuse large cell B-cell lymphomas, 27 follicular lymphomas, 9 plasmacytomas, 9 lymphoplasmocytic lymphoma/immunocytomas and 8 mantle cell lymphomas. The median follow-up time was 44.5 months. Most OAL patients had Stage IE disease and were treated with radiotherapy. Thirty-seven (25%) Stage IE patients had tumour relapses: these were significantly associated with an increased BCL6 blast percentage. Sixty-two (42%) Stage IE patients developed systemic disease: they had "non-EMZL" with large growth fractions and increased blast percentages for BCL6. Fifty-seven (25%) OAL patients died because of their lymphoma; lymphoma-related death was significantly associated on multivariable analysis with advanced clinical stage, an age >60 years and large tumour growth fractions.
conclusionSubtyping of OAL according to the new WHO Lymphoma Classification, the stage of disease and tumour cell growth fraction aided the prediction of (1) tumour relapse, (2) the development of systemic disease and (3) lymphoma-related death in OAL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.